We review common claims about peptide regulation and show the correct wording with controlling sources.
“The FDA advisory committee voted to approve the peptide.”
An FDA advisory committee vote is a recommendation only. FDA makes the final approval decision, and a recommendation does not change the legal status of a substance.
“Compounded tirzepatide and semaglutide are still legal now that the shortages are over.”
FDA resolved the national shortages of tirzepatide (Dec. 19, 2024) and semaglutide (Feb. 21, 2025). After transition periods, compounded copies are generally subject to the usual 503A/503B copy restrictions; local stock-outs do not create a continuing shortage.
“BPC-157 is FDA approved / legal to use / a safe peptide.”
As of September 27, 2024, BPC-157 is not an FDA-approved drug, is in Category 2 of the 503A bulk list (significant safety risks), and is prohibited at all times in sport under WADA S0.
“A product labeled 'research use only' or 'not for human use' is not an FDA-regulated drug.”
FDA looks at intended use, including website claims and marketing context. If the evidence shows the product is intended for human disease treatment, the 'research use only' label does not make it lawful.